has been an active healthcare investor with a focus on medical technology and biotech and he
has been a valued investor and advisor to ReGen Biologics
since 1992.Bill will be an important strategic contributor as ReGen
continues to develop and bring to market groundbreaking technologies in the area of human tissue repair."
is a leading orthopedic products company that develops and manufactures tissue repair products for unmet markets, both in the U.S. and globally.ReGen's first product using its patented core technology is the CMI, which uses the body's own healing process to grow new meniscus tissue and restore mobility for patients with meniscus loss.ReGen
expects to begin modular submission to the FDA
of its PMA for the CMI in Q3 2004 and conclude with submission of the clinical module in Q1 or Q2 2005.The CMI is currently distributed in Europe, Australia, Chile and certain other countries through the Centerpulse
unit of Zimmer Holdings, Inc.
is headquartered in Franklin Lakes, NJ and manufactures the CMI in its ISO Certified facility located in Redwood City, CA.
For more information on ReGen
, visit www.regenbio.com, call (201) 651-5140, or email firstname.lastname@example.org.
Such statements are based on the current expectations and beliefs of the managements of ReGen
and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's annual report on Form 10-K, filed with the Securities and Exchange Commission
on March 30, 2004.